Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

Tamaki, Nobuharu; Kurosaki, Masayuki; Loomba, Rohit; Izumi, Namiki

doi:10.3343/alm.2021.41.1.16

Cited by 30 publications

(42 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, Tamaki et al indicated that positive predictive values for significant fibrosis (≥F2) with cutoff M2BPGi levels of ≥1.0, ≥1.1, ≥1.2, ≥1.3, ≥1.4, and ≥1.5 were 29.2%, 36.4%, 43.5%, 42.9%, 62.5%, and 71.4%, respectively [ 17 ]. Furthermore, as the cutoff M2BPGi level for predicting advanced fibrosis (≥F3) in NAFLD was lower than that for predicting advanced fibrosis in chronic hepatitis C, the underlying liver disease must be considered when interpreting M2BPGi results [ 9 ]. As most data for M2BPGi cutoffs are based on patients attending liver clinics, little data has been obtained from health checkup subjects.…”

Section: Discussionmentioning

confidence: 99%

“…Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel serum fibrosis marker identified in 2013. Mac-2-binding protein (M2BP) is a glycoprotein secreted from hepatic stellate cells, and specific glycan structures of M2BP change as liver fibrosis progresses [ 9 ]. The clinical use has rapidly increased in recent years mainly in Asia.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis

et al. 2021

View full text Add to dashboard Cite

Liver-related mortality rates in patients with non-alcoholic steatohepatitis (NASH) increase with advancing liver fibrosis stage. The present study aimed to elucidate whether adding non-invasive liver fibrosis tests to a comprehensive health checkup system is useful for NASH screening. Both serum Mac-2-binding protein glycosylation isomer (M2BPGi) and point shear wave elastography (pSWE) using ultrasonography were performed for 483 health checkup subjects who consented to participate in this prospective study. Outcomes in positive subjects were surveyed 1 year later. Eighty-eight subjects (18%) showed positive results for at least one liver fibrosis test, with 63 subjects positive for pSWE, 33 subjects positive for M2BPGi, and 72 subjects showing no significant elevation of liver enzymes. The secondary consultation rate for positive subjects was 52% (46/88). However, as 15 of those 46 subjects visited a non-liver-specialist and could not undergo detailed examination, the secondary examination rate was only 35% (31/88). For the 31 subjects who received secondary examination, NASH was diagnosed in 14 subjects, other chronic liver disease (CLD) in 6 subjects, and no CLD in 11 subjects. Additional liver fibrosis tests using M2BPGi and pSWE appear useful in health checkups when screening for CLD, especially for NASH.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Therefore, undetectable HBV DNA may be used as a factor constituting a predictive model for HCC development. Furthermore, previous reports showed that HBsAg, [20][21][22] HBcrAg, [21][22][23] HBV DNA level, 19,24 liver stiffness 25 and M2BPGi [26][27][28][29][30] during treatment were useful for stratification of carcinogenic risk. Future studies are required to determine whether a more accurate carcinogenic risk prediction model could be constructed by combining these scores with PAGE-B.…”

Section: Predictability Of Risk Models For Hcc Developmentmentioning

confidence: 99%

Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment

Kirino

Tamaki

Kurosaki

et al. 2021

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

Carcinogenesis risk scores for chronic hepatitis B have been proposed, but it remains unclear whether these scores during nucleoside/nucleotide analogue (NA) therapy are useful for risk assessment. In this study, we examined changes of these scores and the predictability during NA treatment. 432 patients with no history of hepatocellular carcinoma (HCC) treated with NA were enrolled. PAGE-B, modified PAGE-B (mPAGE-B), and REACH-B scores were calculated at NA administration, 1 and 2 years after administration. The median follow-up duration was 5.1 years, during which 37 patients (8.6%) developed HCC. Cumulative incidence HCC development in patients with high risk of PAGE at NA administration, and 1 and 2 years after NA administration was significantly higher than those with intermediate and low-risk groups (p < .05 for all time points), whereas HCC incidence in patients with high risk of mPAGE-B and REACH-B at 2 years after NA administration were equivalent to those with intermediate and low-risk groups (p = .2 for mPAGE-B, and p = .1 for REACH-B). The area under the receiver operating characteristic (AUROC)

show abstract

“…Mac-2 binding protein glycosylation isomer (M2BPGi) is a liver fibrosis biomarker and its serum levels are correlated with fibrosis progression in chronic liver diseases. Previous studies showed that M2BPGi measurement could be used to predict hepatocellular carcinoma (HCC) development, HCC recurrence risk, and the presence of esophagogastric varices [12,13]. The role of M2BPGi as a non-invasive test for detecting esophageal varices with a high risk of bleeding is not fully explored.…”

Section: Introductionmentioning

confidence: 99%

Mac-2 Binding Protein Glycosylation Isomer for Screening High-Risk Esophageal Varices in Liver Cirrhotic Patient

Nababan

Kalista

Jasirwan

et al. 2021

Livers

View full text Add to dashboard Cite

Background: Esophageal varices occur at middle to advanced stages of cirrhosis and are associated with increased mortality due to their potential for rupture and bleeding. The aim of this study is to examine the accuracy of a surrogate marker, Mac-2 binding protein glycosylation isomer (M2BPGi), for screening high-risk esophageal varices in cirrhotic patients. Methods: Ninety-four cirrhotic patients who underwent endoscopy screening at Cipto Mangunkusumo Hospital, Jakarta, Indonesia were included. Patients with a history of ligation, portal vein thrombosis, or hepatocellular carcinoma were excluded. All enrolled patients underwent ultrasonography, transient elastography, and laboratory tests. The HISCL-5000 Sysmex analyzer was used to measure M2BPGi levels. Results: Of these 94 patients, 27 had high-risk esophageal varices and 67 had non-high-risk esophageal varices. M2BPGi levels were higher in patients with high-risk esophageal varices compared with those with non-high-risk esophageal varices (cutoff index (COI) of 11.4 vs. 3.7, p < 0.001). The sensitivity, specificity, positive predictive value, and negative predictive value of M2BPGi with a cutoff value of 5 COI was 92.6%, 70.1%, 55.6%, and 95.9%, respectively. Conclusions: M2BPGi could be used as a non-invasive surrogate marker for ruling out high-risk esophageal varices in cirrhotic patients. This method is cheap and non-invasive and could be used as a screening tool in resource-limited settings.

show abstract

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

Cited by 30 publications

References 103 publications

Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis

Measurements of Serum Mac-2-Binding Protein Glycosylation Isomer and Shear Wave Velocity in Health Checkups Are Useful in Screening for Non-Alcoholic Steatohepatitis

Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment

Mac-2 Binding Protein Glycosylation Isomer for Screening High-Risk Esophageal Varices in Liver Cirrhotic Patient

Contact Info

Product

Resources

About